Please assess the completion status of the following clinical trial:

Trial Title: S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Morphologically confirmed acute promyelocytic leukemia (APL) based on bone marrow examination~  * APL-RARα-negative by RT-PCR are not eligible~* High-risk disease, defined as WBC \> 100,000/mm\^3~* Bone marrow specimens must be made available for cytogenetic studies~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No prolonged QTc \> 0.47 sec~* No other malignancy within the past 5 years, except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or stage II cancer from which the patients is currently in complete remission~PRIOR CONCURRENT THERAPY:~* No prior systemic chemotherapy for acute leukemia~  * At least 3 days since prior tretinoin (ATRA) allowed~* Prior hydroxyurea, corticosteroids, or leukapheresis to control high cell counts allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Induction:~ATRA 45mg/m2 PO D1-CR Gemtuzumab Ozogamicin 9 mg/m2 IV D1 Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk D10-CR~Consolidation 1 and 2:~Arsenic Trioxide 0.15 mg/kg/d IV 5days/wk x 5 weeks, repeat after 2 weeks rest~Consolidation 2 and 3:~ATRA 45 mg/m2 PO D1-7 Daunomycin 50 mg/m2/d IV D1-3~Consolidation 5 and 6:~GO 9mg/m2 IV D1~Maintenance:~ATRA 45 mg/m2/d PO D1-7 every 14 days 6-MP 60 mg/m2/d PO daily for 1 year Methotrexate 20 mg/m2 PO once/wk for 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).